Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023;21(3):211-217.
doi: 10.2174/1570161121666230328110215.

Effects of Xuezhikang versus Pravastatin on Triglyceride Level in Patients with T2DM and Dyslipidemia: Study Protocol for a Multicenter Randomized Controlled Trial

Jin Xu  1   2   3   4 , Liyuan Zhu  1   2   3   4 , Yingying Xie  1   2   3   4 , Miao Zhang  1   2   3   4 , Zixi Xiao  1   2   3   4 , Rongkai Su  1   2   3   4 , Tie Wen  5   6 , Ling Liu  1   2   3   4
Affiliations

Effects of Xuezhikang versus Pravastatin on Triglyceride Level in Patients with T2DM and Dyslipidemia: Study Protocol for a Multicenter Randomized Controlled Trial

Jin Xu et al. Curr Vasc Pharmacol. 2023.

Abstract

Background: Hypertriglyceridemia, is commonly found in patients with diabetes. Xuezhikang, an extract of red yeast rice, is effective in reducing cardiovascular events in Chinese patients with diabetes and coronary heart disease (CHD). Xuezhikang has been reported to significantly decrease the level of triglycerides (TG), a potential causal risk factor for myocardial infarction. On the basis of a similar reduction in low-density lipoprotein cholesterol, this study will evaluate the effect of xuezhikang on TG levels compared with pravastatin in patients with type 2 diabetes mellitus (T2DM) and dyslipidemia.

Methods: This is an open-label, multicenter, randomized controlled study to assess the effects of xuezhikang (1.2 g/day) and pravastatin (20 mg/day) on TG and other blood lipid parameters in patients with T2DM and dyslipidemia. A total of 114 patients will be enrolled and randomly assigned 1:1 to receive xuezhikang or pravastatin treatment for 6 weeks.

Result: The primary outcome measure is the change from baseline in fasting TG levels after 6 weeks. The change from baseline in other fasting and postprandial lipid parameters, and glucose profiles at 1, 2, and 4 h after a nutritious breakfast will also be explored.

Conclusion: This study will evaluate the effect of a 6-week treatment with xuezhikang compared with pravastatin on fasting and postprandial TG levels and other blood lipid parameters in patients with T2DM and dyslipidemia without atherosclerotic cardiovascular disease (ASCVD). The results will provide more information on optimizing the lipid control of patients with diabetes in the primary prevention of ASCVD.

Keywords: Diabetes; cardiovascular risk; diabetes.; dyslipidemia; hypertriglyceridemia; triglyceride.

PubMed Disclaimer

Conflict of interest statement

The authors declared that they have no competing interests.

Figures

Fig. (1)
Fig. (1)
Study design. Abbreviations: T2DM, type 2 diabetes mellitus; V, Visit.
See this image and copyright information in PMC

References

    1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486–2497. doi: 10.1001/jama.285.19.2486. - DOI - PubMed
    1. Cosentino F., Grant P.J., Aboyans V., et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur. Heart J. 2020;41(2):255–323. doi: 10.1093/eurheartj/ehz486. - DOI - PubMed
    1. Athyros V.G., Doumas M., Imprialos K.P., et al. Diabetes and lipid metabolism. Hormones (Athens) 2018;17(1):61–67. doi: 10.1007/s42000-018-0014-8. - DOI - PubMed
    1. Tomlinson B., Patil N.G., Fok M., Lam C.W.K. Managing dyslipidemia in patients with Type 2 diabetes. Expert Opin. Pharmacother. 2021;22(16):2221–2234. doi: 10.1080/14656566.2021.1912734. - DOI - PubMed
    1. Chait A., Ginsberg H.N., Vaisar T., Heinecke J.W., Goldberg I.J., Bornfeldt K.E. Remnants of the triglyceride-rich lipoproteins, diabetes, and cardiovascular disease. Diabetes. 2020;69(4):508–516. doi: 10.2337/dbi19-0007. - DOI - PMC - PubMed

Publication types